SECsense Logo

Marker Therapeutics, Inc. 8-K Filing: Key Insights on Corporate Developments

$MRKR
Form 8-K
Filed on: 2024-12-19
Source
Marker Therapeutics, Inc. 8-K Filing: Key Insights on Corporate Developments

Based on the provided financial report section, here are the key extracted details and insights:

  1. Entity Information:
  • Company Name: Marker Therapeutics, Inc.
  • CIK (Central Index Key): 0001094038
  • Industry: Biotechnology (implied by the company name)
  • Address: 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, TX 77021
  • Contact Number: 713-400-6400
  1. Filing Details:
  • Filing Type: 8-K
  • Filing Date: December 19, 2024
  • SEC File Number: 001-37939
  • EIN: 45-4497941
  1. Stock Information:
  • Common Stock Par Value: $0.001 per share
  • Ticker Symbol: MRKR
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: December 19, 2024
  • End Date: December 19, 2024
  • Context ID: AsOf2024-12-19
  1. Financial Units:
  • Currency: USD (U.S. Dollars)
  • Measurement Units: Shares (for stocks)
  1. Key Insights:
  • The report indicates that Marker Therapeutics, Inc. has filed an 8-K, which typically covers significant events that shareholders should be aware of. The specific details of the filing are not included, but this type of filing often involves company announcements, changes in executive leadership, or other important corporate events.
  • The company's registration and listing on NASDAQ suggest it is publicly traded, providing liquidity for its investors.
  • The par value of the common stock is relatively low, which is common in modern corporate finance, as companies often set minimal par values.

Overall, this section indicates that Marker Therapeutics, Inc. is actively engaged in reporting to the SEC and is maintaining its public company obligations while being listed on a major exchange. Further details from the 8-K filing would be needed to understand the specific events or disclosures that prompted this filing.